Search results for: Multi-Indication Medicines
Filter search results
Prescribing, Budgets and Fundholding in General Practice
10 January 1997
…practice was a particular focus of attention. The preparatory White Paper (CM 555, 1989) noted that prescription medicines formed the largest single expenditure item for the Family Practitioner Services and…
Pharmaceuticals in seven nations
1 May 1985
…the reader’s attention is drawn to Pharmaceuticals among problems of supplying medicines to the Third World have been extensively discussed elsewhere (see, for example, Medicines, Health and the Poor World…
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
1 June 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies….
A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
1 July 2020
…economic value of new medicines between consumers (payers) and developers (life science… This paper presents a supply and demand model of pharmaceutical markets to analyse the relationship between the value…
Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize
25 January 2023
…medicines?’. Professor Hollis’ winning entry proposed a novel solution where the price paid is not directly tied to the reward that the innovator of a medicine receives. This could increase…
Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?
27 July 2023
…BCG vaccination program, the use of chest radiology and sputum examination, and the availability and use of new medicines. This highlighted how the NHS could improve health through PREVENTION, DETECTION…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…is seen most clearly when costs and benefits occur at different points in time. In a healthcare context, this is most apparent when evaluating advanced therapy medicinal products (ATMPs), medicines…
Dr. Jacoline Bouvy
19 March 2024
Dr. Jacoline Bouvy is the Programme Director of Medicines Evaluation at the National Institute for Health and Care Excellence (NICE). She is responsible for the delivery of medicines guidance produced…
Around the world in HTAs: China – From fragmentation to function
2 September 2025
…List (NRDL), which determines which medicines are eligible for coverage under the two major public insurance schemes. Prior to 2017, the NRDL was updated infrequently and through a highly opaque…